Heart Failure
Conditions
Keywords
heart failure, telemonitoring
Brief summary
CARDIAUVERGNE is a heart failure telemonitoring system at Clermont-Ferrand's hospital. The aim of this study is to analyze the prognosis and evolution of patients after exclusion of telemonitoring. The patients were included from 1st January 2023 to 31st December 2024 and the monitoring was terminated for end of eligibility according to the French health authority criteria.
Detailed description
After an episode of heart failure, patients have been included in a telemonitoring program in order to reduce rehospitalizations for heart failure and improve follow-up. On a daily basis, the patients weigh themselves on connected scales which enables a team of dedicated nurses to follow them closely. If need be they can call the patient, ask for a blood exam and adapt their prescription. Indeed, if remote support is insufficient, patients can be hospitalized prematurely and so decrease the duration of hospital care. The inclusion criteria correspond to either an episode of heart failure in the last 12 months or dyspnea at least New York Heart Association (NYHA) 2 with NT-proBNP over 1000pg/mL. The follow up is renewed every 6 months. Patients are excluded from monitoring when criteria are no longer fulfilled. As these characteristics have been chosen empirically, our aim is to see if patients no longer presenting these standards have indeed a low chance of bad evolution. Information is gathered from their medical record at inclusion, exclusion and 1 year after exclusion. A short phone call is made after 1 year of exclusion, to appreciate their evolution and gather information concerning their symptoms, treatments ...
Interventions
None listed
Sponsors
University Hospital, Clermont-Ferrand
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adults * able to read and understand french * included in CARDIAUVERGNE telemonitoring program from 1st january 2023 to 31st december 2024 such as defined by the french health authorithy criteria (heart failure within 12 months or dyspnea at least NYHA 2 associated with NTproBNP of at least 1000pg/mL) and excluded by medical decision as no longer presenting eligibillity criteria
Exclusion criteria
* Patients leaving telemonitoring for other reasons (choice, death, medical reason, relocation, inobservance)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite criterion defined by the occurrence within one year following the end of remote monitoring of either cardiovascular death or heart failure worsening (hospitalization or unscheduled visit for heart failure) | From telemonitoring exclusion up to a year after |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Amount of medical appointments | From telemonitoring exclusion up to a year after | General practician and cardiology consultations |
| Natriuretic peptides, NTproBNP, evolution | From inclusion until a year after exclusion | NTproBNP comparison at inclusion, exclusion and a year after exclusion for monitoring |
| Number of patients that could theoretically be re-included during follow up | From telemonitoring exclusion up to a year after | — |
| Determination of potential patient profiles more suitable to discontinue remote monitoring | From inclusion up to a year after telemonitoring exclusion | — |
Countries
France
Contacts
CONTACTLise Laclautre
PRINCIPAL_INVESTIGATORClément RIOCREUX
University Hospital, Clermont-Ferrand
Outcome results
None listed